Celltrion's Yuflyma gains FDA approval for interchangeability with Humira, boosting its competitive edge in the lucrative U.S. autoimmune disease treatment market
#YonhapInfomax #Celltrion #Yuflyma #Humira #Interchangeability #FDAApproval #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=58524